Graf Acquisition Corp. Warrant (NKGNW)

Overview

NKGen Biotech, Inc. is a distinguished clinical-stage biotechnology entity specializing in pioneering the development and commercialization of innovative cancer treatments based on natural killer (NK) cell therapies. The company has a rich pipeline of both autologous and allogeneic, as well as chimeric antigen receptor (CAR)-NK cell therapies designed to target a range of malignancies and other diseases. Originating from its roots as NKMAX America, Inc., NKGen Biotech has directed its focus towards leveraging the therapeutic potentials of NK cells since its establishment in 2017. The company operates under the ownership of NKMAX Co., Ltd. and is strategically headquartered in Santa Ana, California. Through its vital license agreement with NKMAX, NKGen Biotech, Inc. stands at the forefront of advancing NK cell therapy technologies with the aim to transform the landscape of cancer treatment.

Products and Services

• SNK01 - An autologous NK cell therapy candidate, SNK01 takes center stage in NKGen Biotech's product lineup as a revolutionary treatment approach for neurodegenerative diseases. Utilizing the patient's own natural killer cells, this therapy is engineered to target and potentially halt the progression of various neurodegenerative disorders, showcasing the versatile applications of NK cell therapies beyond cancer.
• SNK02 - Marking the company’s venture into allogeneic NK cell therapies, SNK02 is currently in Phase 1 clinical trials targeting refractory solid tumors. This therapy represents a significant stride in cancer treatment, employing donor-derived NK cells to fight against solid tumors that are resistant to conventional therapies. As it moves through clinical trials, SNK02 positions NKGen Biotech at the leading edge of exploring the full therapeutic potential of NK cells against a broad spectrum of cancers.